Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Senegal’s Hidden Debt Shock

    Dan Wood speaks to us from Senegal, where bond-market volatility has spiked due to the declaration of a previously hidden stockpile of government debt.

    Watch the video

  • How Generative AI Could Rewrite the Software Playbook

    Generative AI could transform the software industry by accelerating workflows, enhancing client engagement, and creating new revenue opportunities—moving tasks that once took hours to just seconds.

    Watch the video

  • CIH Has Agreed to be Acquired by Tokio Marine

    William Blair acted as exclusive financial advisor to Commodity & Ingredient Hedging, LLC, a portfolio company of Falfurrias Capital Partners, in connection with its pending sale to Tokio Marine Holdings, Inc.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures